Together, our results indicate that SJ-288 displays poor metabolic stability, whereas the pharmacodynamics and targeted inhibitory action of SJ-300 against the DKK3-LRP1 interaction support its further development as a promising candidate for AD therapy. This evidence concerns the gene DKK3 and Alzheimer disease.